ANNUAL REPORT 2009-2010 - University of Toronto Department of ...

ANNUAL REPORT 2009-2010
Holtzman S (PI); Barata P, Stewart DE. Understanding and measuring the construct of irritability
in men and women. Canadian Institutes of Health Research, $98,940, March 1, 2010 – February
28, 2011.
Ickowicz A, Weksberg R (Co-PI), Butcher D. Identifying epigenetic targets of lithium: An invitro
pilot study. Psychiatric Endowment Fund, $23,375, 2009 – 2010.
Janssen P, Lee SK. Antepartum Care of High Risk Pregnancy Team. Canadian Institutes of
Health Research, $213,000, 2008 – 2011.
Jenkins D, Gaisano H. (Primary Applicants), Belsham DD (Co-Applicant). Diet, the Digestive
tract and Disease: The 3D Centre. Canadian Foundation for Innovation, New Initiatives Fund
2009, $5,437,276, June 16, 2009.
Jones JM, Howell DM (Principal Investigators); Buchman SH, Catton P, Earle CC, Ferguson S,
Fitzgerald BJ, Gagliardi AR, Gospodarowicz M, Harrison MB, Jadad AR; Jusko Friedman A,
Sharpe MB, Urowitz S, Warde PR, Wiljer DE (Co-Investigators). Transition to Survivorship:
Translating knowledge into action for testicular and endometrial cancer populations. CIHR,
Operating Grant, $311,007 total; $103,669 per annum, 2010 – 2013.
Jones R (PI), Lye S, Shynlova O. Identification of early triggers of decidual activation in preterm
labour. Tommy’s, The Baby Charity, Operating grant, $298,391; $99,464 per annum, November
1, 2008 – October 31, 2011.
Josse R (Principal Investigator), Derzko C, Murray TM, Rubin L (Co-Investigators). Fracture
incidence reduction and safety of TSE-424 (bazedoxifene acetate) compared to placebo and
raloxifene in osteoporotic postmenopausal women. Wyeth Protocol 3068A1-301-CA. $17,000 per
patient, 2002 – ongoing.
Josse R (Principal Investigator), Derzko CM, Rubin L (Co-Investigators). The efficacy and
safety of 2g strontium ranelate in the treatment of male osteoporosis: A prospective multicentre,
international, double-blind, placebo-controlled study with a treatment duration of 2 years and the
main study analysis after 1 year. Servier Protocol CL3-12911-032 Total operating budget: $6,995
per patient, 2007 – ongoing.
Josse R (Principal Investigator), Derzko CM, Rubin L (Co-Investigators). 52 week randomized
double-blind, multicenter,mechanistic study with a 24 week open label follow-up to evaluate the
effect of AVANDIA on bone in postmenopausal women with type 2 diabetes mellitus.
GlaxoSmithKline Protocol ZM2007/00146/00, 2008 – 2010.
Josse R (Principal Investigator), Derzko CM, Rubin L (Co-Investigators). A randomized openlabel
study to evaluate the safety and efficacy of denosumab and monthly actonel therapies in
postmenopausal women transitioned from weekly or daily alendronate therapy. Amgen Protocol
20080099. $5,456 per patient, 2009-ongoing.
Jurisica I, Oza AM (Principal Investigators), Colgan TJ, Jurisicova A, Kislinger T (Co-
Applicants). Diagnostic and prognostic biomarkers for epithelial ovarian cancer. Canadian
Institutes of Health Research, Operating Grant, $161,125 per annum, 2009 – 2013.
Jurisicova A. Canada Research Chair. CIHR, $175,000, July 1, 2008 – June 30, 2013.
123